Argent Biopharma (AU:RGT)
ASX:RGT
RGT Stock Chart & Stats
AU$0.08
>-AU$0.01(-2.00%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.32
Previous CloseN/A
Volume362.25K
Average Volume (3M)77.74K
Market Cap
AU$3.57M
Enterprise ValueAU$10.30M
Total Cash (Recent Filing)AU$1.02M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)―
Beta-0.77
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding89,192,314
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross Margin (2025)A materially higher gross margin in 2025 indicates the company’s underlying product economics can be attractive even at lower volumes. If management stabilizes revenue or cuts overhead, the stronger gross margin provides a durable lever to improve operating profitability and cash conversion over the next several quarters.
Industry: Specialty & Generic DrugsOperating in specialty and generic pharmaceuticals exposes the firm to structural demand for niche therapies and recurring prescription flows. These segments can provide durable revenue pools and pricing flexibility versus commoditized markets, supporting longer-term recovery if product traction and regulatory pathways are managed.
Prior Positive Equity (2022)Having reported positive equity as recently as 2022 suggests the company previously reached a healthier capital structure, implying existing assets or IP that supported solvency. That historical solvency means restructuring, recapitalization, or asset monetization could restore balance-sheet health rather than starting from a permanently impaired base.
Bears Say
Negative Shareholders' EquitySustained negative equity undermines creditor and investor confidence and constrains financing options. It raises the risk of dilution or distressed capital raises, limits ability to fund R&D or commercialization internally, and represents a persistent solvency concern unless reversed through material profits or capital injections.
Sustained Free Cash Flow BurnLarge, persistent negative free cash flow indicates the business cannot self-fund operations or investments, creating ongoing reliance on external financing. Over a multi-quarter horizon this raises execution risk, potential dilution from equity raises, and the chance that critical projects are underfunded if capital markets tighten.
Sharp Revenue Contraction And Heavy LossesA steep multi-year revenue decline combined with large operating losses signals loss of product demand or commercialization failure. Structural recovery requires regaining meaningful top-line scale; until revenue stabilizes, fixed costs will continue to overwhelm gross margins and impede a durable path to profitability.
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.03 and its highest was AU$0.32 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$3.57M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 27, 2026 which is in 140 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.038.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 89,192,314 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:RGT Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
258.94%
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―